Market Cap | 61.14M | P/E | 11.95 | EPS this Y | - | Ern Qtrly Grth | - |
Income | -21.27M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 19.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 19.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -44.00% |
Recommedations | 2.00 | Quick Ratio | 0.51 | Shares Outstanding | 36.09M | 52W Low Chg | 83.00% |
Insider Own | 32.54% | ROA | -168.04% | Shares Float | 20.21M | Beta | -0.89 |
Inst Own | 13.27% | ROE | -485.13% | Shares Shorted/Prior | 174.31K/39.72K | Price | 11.95 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 25,647 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 1,176,367 | Change | 44.67% |
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Ladenburg Thalmann | Buy | Sep 22, 23 |
EF Hutton | Buy | May 18, 23 |
EF Hutton | Buy | May 10, 23 |
JonesTrading | Buy | Apr 19, 23 |
EF Hutton | Buy | Apr 5, 23 |
EF Hutton | Buy | Mar 29, 23 |
EF Hutton | Buy | Dec 13, 22 |
EF Hutton | Buy | Dec 12, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Cogley Brian | Chief Financial Offi.. Chief Financial Officer | Jan 10 | Buy | .67 | 5,000 | 3,350 | 30,000 | 01/17/24 |
DeSilva Tara | Director Director | Jan 12 | Buy | 0.57 | 2,266 | 1,292 | 32,266 | 01/16/24 |
Yerace Daniel Alexander | VP of Operations VP of Operations | Jan 05 | Buy | .69 | 10,850 | 7,486 | 1,071,455 | 01/09/24 |
Salkind Gene | Director Director | Jan 05 | Buy | .69 | 11,600 | 8,004 | 284,056 | 01/09/24 |
Mehalick David | CEO and President CEO and President | Jan 05 | Buy | 0.67 | 25,054 | 16,786 | 2,782,615 | 01/09/24 |
Harraden Circle Investments, L... | 10% Owner 10% Owner | May 04 | Sell | 10.11 | 85,305 | 862,434 | 429,131 | 05/06/22 |